Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 48

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 48
---
 of the FutureTech Board, reasonable, and represent a strong commitment by FutureTech and Longevity to complete the Business Combination. The FutureTech Board also considered the financial and other terms of the Merger Agreement and the fact that such terms and conditions are, in their view, reasonable and were the product of arm’s-length negotiations between FutureTech and Longevity. Although the FutureTech Board believes that the Business Combination with Longevity presents an attractive business combination opportunity and is in the best interests of FutureTech and its stockholders, the FutureTech Board did consider certain potentially material negative factors in arriving at that conclusion, including, among others:

| 7 |

Macroeconomic and Geopolitical Risks.Potential economic downturns caused by tarriff wars, geopolitical uncertainty, and market conditions beyond FutureTech’s control, including a reduction in economic activity and incease of government employee layoffs, economic effects of trade wars, and the Russia-Ukraine conflict could adversely affect business, financial condition, results of operations and prospects of FutureTech and Longevity.

Business Risks. The risks, although not weighted and not presented in any order of significance, associated with successful implementation of Longevity’s long-term business plan and strategy and Longevity realizing the anticipated benefits of the Business Combination on the timeline expected or at all, including but not limited to (i) the availability of additional capital to fund Longevity’s growth organically and through strategic acquisitions; (iii) Longevity’s ability to maintain, protect and enhance its brand; (iv) Longevity’s ability to manage growth effectively, including its ability to recruit and train its sales, commercial and marketing, technology, and finance and administration teams and refine Longevity’s operational, financial and risk management controls and reporting systems and procedures as it grows; and (v) factors outside of the parties’ control, such as climate risks, fluctuations in interest, inflation and exchange rates and the potential negative impact of logistics and suppliers disruptions from trade wars, uncertainty in the Middle East and the Russia-Ukraine conflict.

In this regard, FutureTech Board also considered risks relating to obtaining and maintaining necessary regulatory approvals for commercializing Longevity’s treatments, the effect of competing clinical, technological and market developments, the outcomes of ongoing and future clinical trials relating to Longevity’s pipeline and rights to use and the ability to protect intellectual property used in Longevity’s business and products, among others and the combined company realizing the anticipated benefits of the Business Combination on the timeline expected or at all, including due to factors outside of the parties